SUBSCRIBE
SUBSCRIBE
News   Drug Development

Unique Structure Of Geron Corporation’s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity In Lung Cancer Cells

February 15, 2007 | 
1 min read
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti-tumor and anti-metastatic activity.
Preclinical
MORE ON THIS TOPIC
Hand holds a cut-out puzzle piece shaped like a human brain, backlit by sunlight against a bright yellow background, symbolizing creativity and problem-solving.
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
December 11, 2025
 · 
1 min read
 · 
Annalee Armstrong
Dartboard with three darts in the bullseyes. 3D illustration
Obesity
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
December 11, 2025
 · 
3 min read
 · 
Annalee Armstrong
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Roche Diagnostics building in California
Breast cancer
Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac